Trial Profile
Efficacy of entecavir as an adjuvant therapy for hepatocellular carcinoma derived from HBV infection: a prospective trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2019
Price :
$35
*
At a glance
- Drugs Entecavir (Primary)
- Indications Hepatitis B; Liver cancer
- Focus Therapeutic Use
- Acronyms ETV-HCC
- 22 Jan 2019 Status changed from recruiting to completed.
- 21 Jul 2011 New trial record